Kerala Ayurveda Limited reported a consolidated net loss of ₹8.08 crore for the quarter ended June 30, 2026 (Q1FY26), widening significantly from a net loss of ₹2.03 crore in the corresponding period of FY25. Standalone results showed a net loss of ₹7.67 crore compared to a profit of ₹2.07 crore in Q1FY25, driven by rising operational costs and increased finance expenses. The Board of Directors approved these unaudited financial results on August 12, 2026, alongside the amalgamation of its wellness subsidiary and an employee stock option grant.

The company’s standalone revenue from operations fell to ₹22.53 crore in Q1FY26, down from ₹24.57 crore in Q4FY26 and ₹17.57 crore in Q1FY25. Total expenses rose to ₹31.84 crore from ₹24.99 crore year-on-year, primarily due to a surge in employee benefits expense to ₹13.18 crore and finance costs increasing to ₹2.81 crore. Consolidated revenue from operations stood at ₹33.19 crore, slightly lower than the ₹34.74 crore reported in the preceding quarter but up from ₹28.61 crore in Q1FY25.

Beyond financial results, the Board approved the Scheme of Amalgamation between Kerala Ayurveda Limited and its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre Private Limited. The merger, subject to shareholder and National Company Law Tribunal approval, aims to streamline operations, reduce regulatory compliances, and integrate assets including intellectual property. The transaction does not fall under related-party transaction regulations as it involves a holding company and its wholly-owned subsidiary.

The Nomination and Remuneration Committee granted 64,875 Employee Stock Options under the Kerala Ayurveda Employee Restricted Stock Unit Plan, 2023. The options carry an exercise price of ₹10 per share and vest according to the scheme’s terms, exercisable within one year post-vesting. Additionally, the Board recommended the re-appointment of Non-Executive Director Ramesh Vangal at the ensuing Annual General Meeting on September 28, 2026.

What the Numbers Show

The divergence between standalone profitability trends highlights structural cost pressures within the parent entity. While consolidated revenues grew 16% year-on-year, the standalone segment swung from a profit to a significant loss, indicating that overheads and finance costs are outpacing top-line growth in the core Indian operations. The acquisition of the remaining 26% stake in Ayurvedagram during the period, executed via a share swap of 304,887 equity shares, has fully consolidated this subsidiary, potentially impacting future comparability as its wellness center revenues and margins blend directly into the group’s primary healthcare and pharmaceutical focus.

Kerala Ayurveda Limited has appointed Mr. Binu Thomas as its Company Secretary and Compliance Officer, effective June 9, 2026. The appointment was approved by the Board of Directors during its meeting held on June 9, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Mr. Thomas is a Fellow Member of the Institute of Company Secretaries of India (ICSI) and holds an MBA from Chandigarh University. He has completed a Post Graduate Diploma in Goods and Services Tax (GST) from the Gulati Institute of Finance and Taxation, Thiruvananthapuram, and holds a Diploma in Arbitration. Additionally, he is a Certified CSR Professional from ICSI and has completed certificate courses in Corporate Restructuring, Commercial Contracts Management, Initial Public Offering (IPO), and NBFC Compliances conducted by ICSI.

He possesses over 10 years of post-qualification experience in secretarial and compliance functions of listed entities. Prior to joining Kerala Ayurveda Limited, he was associated with Harrisons Malayalam Limited as Company Secretary and Compliance Officer.

Key Appointment Details